Similar articles for PMID: 12783207

Year	Number of Results
1987	1
1993	1
1994	1
1998	1
1999	1
2000	1
2001	3
2002	12
2003	31
2004	16
2005	12
2006	11
2007	15
2008	9
2009	10
2010	9
2011	7
2012	5
2013	16
2014	14
2015	7
2016	5
2017	8
2018	4
2019	4
2020	5
2021	6
2022	2
2024	0

1

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.

Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2003 Sep;52(3):229-34. doi: 10.1007/s00280-003-0651-7. Epub 2003 May 29. Cancer Chemother Pharmacol. 2003. PMID: 12783207

2

[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].

Voglová J, Maisnar V, Beránek M, Chrobák L. Voglová J, et al. Vnitr Lek. 2006 Sep;52(9):819-22. Vnitr Lek. 2006. PMID: 17091608 Czech.

3

Spotlight on imatinib mesylate in chronic myeloid leukemia.

Curran MP, Croom KF, Goa KL. Curran MP, et al. BioDrugs. 2004;18(3):207-10. doi: 10.2165/00063030-200418030-00009. BioDrugs. 2004. PMID: 15161340 Review.

4

U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.

Cohen MH, Johnson JR, Pazdur R. Cohen MH, et al. Clin Cancer Res. 2005 Jan 1;11(1):12-9. Clin Cancer Res. 2005. PMID: 15671523 Clinical Trial.

5

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.

6

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C. Fausel C. J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. doi: 10.18553/jmcp.2007.13.s8-a.8. J Manag Care Pharm. 2007. PMID: 17970609 Free PMC article. Review.

7

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Kantarjian HM, et al. Clin Cancer Res. 2002 Jul;8(7):2177-87. Clin Cancer Res. 2002. PMID: 12114418 Clinical Trial.

8

Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.

Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J. Sureda A, et al. Haematologica. 2003 Nov;88(11):1213-20. Haematologica. 2003. PMID: 14607749 Clinical Trial.

9

[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].

Voglová J, Poznarová A, Chrobák L, Rabasová J, Beránek M, Moravcová J, Faber E, Klamová H, Cikhart M. Voglová J, et al. Vnitr Lek. 2004 Jan;50(1):21-3, 26-9. Vnitr Lek. 2004. PMID: 15015226 Clinical Trial. Czech.

10

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD. Zhang GC, et al. Ai Zheng. 2004 Dec;23(12):1696-9. Ai Zheng. 2004. PMID: 15601563 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

202 results

Results by year